Dashboard
Manage Tickers

TSHA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

raymond-james-initiates-coverage-on-taysha-gene-therapies-with-strong-buy-rating-announces-price-target-of-13
Raymond James Initiates Coverage On Taysha...
10/21/2025 17:43:52

Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating...

olema-pharmaceuticals-exelixis-genmab-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Olema Pharmaceuticals, Exelixis, Genmab An...
10/20/2025 12:10:45

why-is-taysha-gene-therapies-stock-falling-friday
Why Is Taysha Gene Therapies Stock Falling...
10/17/2025 16:44:00

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for p...

needham-reiterates-buy-on-taysha-gene-therapies-maintains-10-price-target
Needham Reiterates Buy on Taysha Gene Ther...
10/17/2025 10:37:03

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.

taysha-gene-therapies-regains-full-rights-to-its-lead-tsha-102-program-in-clinical-evaluation-for-rett-syndrome-tsha-102-has-demonstrated-compelling-part-a-reveal-phase-12-safety-and-efficacy-data-received-fda-breakthrough-therapy-designation-and-is-advancing-with-a-clear-path-to-potential-registration
Taysha Gene Therapies Regains Full Rights ...
10/16/2025 20:06:34

DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage b...

taysha-gene-announces-results-from-supplemental-data-analysis-from-part-a-of-reveal-phase-12-adultadolescent-and-pediatric-trials-evaluating-tsha-102-in-females-with-rett-syndrome-at-cns-annual-meeting
Taysha Gene Announces Results From Supplem...
10/09/2025 12:04:56

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥...

demystifying-taysha-gene-therapies-insights-from-6-analyst-reviews
Demystifying Taysha Gene Therapies: Insigh...
10/02/2025 18:01:35

baird-maintains-outperform-on-taysha-gene-therapies-raises-price-target-to-12
Baird Maintains Outperform on Taysha Gene ...
10/02/2025 17:52:42

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 17:06:31

taysha-gene-therapies-canaan-ondas-holdings-and-other-big-stocks-moving-higher-on-thursday
Taysha Gene Therapies, Canaan, Ondas Holdi...
10/02/2025 16:29:57

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

needham-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-10
Needham Maintains Buy on Taysha Gene Thera...
10/02/2025 14:51:58

Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.

top-2-health-care-stocks-that-may-keep-you-up-at-night-this-month
Top 2 Health Care Stocks That May Keep You...
10/02/2025 13:06:22

fda-grants-breakthrough-therapy-designation-to-taysha-gene-therapies-tsha-102-for-rett-syndrome-on-track-to-begin-patient-enrollment-in-q4-2025
FDA Grants Breakthrough Therapy Designatio...
10/02/2025 12:03:48

Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from a...

whats-driving-the-market-sentiment-around-taysha-gene-therapies
What's Driving the Market Sentiment Around...
09/18/2025 17:00:40

is-taysha-gene-therapies-gaining-or-losing-market-support
Is Taysha Gene Therapies Gaining or Losing...
08/25/2025 15:01:04

a-glimpse-into-the-expert-outlook-on-taysha-gene-therapies-through-11-analysts
A Glimpse Into The Expert Outlook On Taysh...
08/13/2025 13:00:41

wells-fargo-maintains-overweight-on-taysha-gene-therapies-raises-price-target-to-8
Wells Fargo Maintains Overweight on Taysha...
08/13/2025 12:53:24

Wells Fargo analyst Yanan Zhu maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and raises the price target fr...

canaccord-genuity-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-14
Canaccord Genuity Maintains Buy on Taysha ...
08/13/2025 10:50:31

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target ...

chardan-capital-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-10
Chardan Capital Maintains Buy on Taysha Ge...
08/12/2025 21:19:51

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target...

taysha-gene-therapies-q2-eps-009-misses-008-estimate-sales-1986m-beat-1765m-estimate
Taysha Gene Therapies Q2 EPS $(0.09) Misse...
08/12/2025 12:01:45

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION